Mizuho Securities Thinks Atara Biotherapeutics’ Stock is Going to Recover

Mizuho Securities analyst Salim Syed maintained a Buy rating on Atara Biotherapeutics (ATRAResearch Report) yesterday and set a price target of $39.00. The company’s shares closed last Tuesday at $9.82, close to its 52-week low of $8.24.

According to TipRanks.com, Syed ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -14.3% and a 36.1% success rate. Syed covers the Healthcare sector, focusing on stocks such as Coherus Biosciences, Unity Biotechnology, and Wave Life Sciences.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Atara Biotherapeutics with a $36.80 average price target.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $20.04 and a one-year low of $8.24. Currently, Atara Biotherapeutics has an average volume of 928.2K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Atara Biotherapeutics, Inc. operates as a clinical stage company, which engages in the development of novel therapeutics for patients with cancer, autoimmune, and viral diseases. Its pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.

Read More on ATRA:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More